| __timestamp | BioMarin Pharmaceutical Inc. | Sarepta Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 302156000 | 49315000 |
| Thursday, January 1, 2015 | 402271000 | 75043000 |
| Friday, January 1, 2016 | 476593000 | 83749000 |
| Sunday, January 1, 2017 | 554336000 | 122682000 |
| Monday, January 1, 2018 | 604353000 | 207761000 |
| Tuesday, January 1, 2019 | 680924000 | 284812000 |
| Wednesday, January 1, 2020 | 737669000 | 317875000 |
| Friday, January 1, 2021 | 759375000 | 282660000 |
| Saturday, January 1, 2022 | 854009000 | 451421000 |
| Sunday, January 1, 2023 | 937300000 | 481871000 |
| Monday, January 1, 2024 | 1009025000 |
Data in motion
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for financial health. Over the past decade, BioMarin Pharmaceutical Inc. and Sarepta Therapeutics, Inc. have shown distinct strategies in handling these costs. From 2014 to 2023, BioMarin's SG&A expenses grew by approximately 210%, peaking in 2023. In contrast, Sarepta's expenses increased by nearly 880% during the same period, reflecting its aggressive expansion strategy. While BioMarin's expenses were consistently higher, their growth rate was more controlled, suggesting a focus on sustainable scaling. Sarepta's rapid increase indicates a bold approach, possibly investing heavily in market penetration and R&D. This comparison highlights the strategic choices companies make in balancing growth and cost management, offering valuable insights for investors and industry analysts alike.
Alnylam Pharmaceuticals, Inc. or Sarepta Therapeutics, Inc.: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of Incyte Corporation and Sarepta Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Summit Therapeutics Inc. and BioMarin Pharmaceutical Inc.
Comparing SG&A Expenses: Insmed Incorporated vs BioMarin Pharmaceutical Inc. Trends and Insights
Cost Management Insights: SG&A Expenses for BioMarin Pharmaceutical Inc. and Ascendis Pharma A/S
Who Optimizes SG&A Costs Better? BioMarin Pharmaceutical Inc. or Madrigal Pharmaceuticals, Inc.
Comparing SG&A Expenses: BioMarin Pharmaceutical Inc. vs Vericel Corporation Trends and Insights
BioMarin Pharmaceutical Inc. and Travere Therapeutics, Inc.: SG&A Spending Patterns Compared
Comparing SG&A Expenses: BioMarin Pharmaceutical Inc. vs Xencor, Inc. Trends and Insights
Who Optimizes SG&A Costs Better? Sarepta Therapeutics, Inc. or Vericel Corporation
Sarepta Therapeutics, Inc. vs Iovance Biotherapeutics, Inc.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing Sarepta Therapeutics, Inc. and Galapagos NV